Bellicum Pharmaceuticals (NASDAQ:BLCM) Earns Sell Rating from Analysts at StockNews.com
StockNews.com initiated coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM – Free Report) in a research report report published on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Bellicum Pharmaceuticals Stock Down 14.9 % Shares of BLCM stock opened at $0.15 on Monday. The firm’s 50 day moving average price is […]
More Stories
How to Use a Snapchat Caption Generator for Creative Stories
Snapchat is all about creativity, spontaneity, and connection. But when you’re constantly snapping and sharing, coming up with fresh, fun,...
Startup Trends to Watch in 2025: New Sectors for Entrepreneurs
Heading into 2025, the world of startups is set to undergo remarkable changes, fuelled by technological evolution and constantly shifting...
How to Unblock TikTok in USA: A Guide for Content Creators
As a content creator, navigating the ever-changing landscape of social media platforms can be a daunting task, especially when faced...
Personal Injury PPC: Targeting the Right Clients at the Right Time
In today’s competitive legal landscape, personal injury lawyers need to be proactive in attracting clients. While organic SEO is essential...
Sudan’s worsening famine: Conflict puts millions at risk
Sudan is confronting a widening famine crisis, with widespread starvation, surging acute malnutrition and mass displacement exacerbating an already dire...
Top 10 Data Science Certifications: A 2025 Guide to Success
Data scientists are among the highest-paid professionals in the world. In the U.S, a data scientist earns an average of...